IceCure Medical Reports Q2 2026 Earnings with Revenue Growth and Expansion
IceCure Medical (ICCM) reported $1.8 million in revenue for the first half of 2026, a 45% increase driven by higher sales of systems and disposable probes. Disposable probe revenue reached $1.1 million due to increased procedural usage among physicians, while system revenue grew from $529,000 to $757,000 as new customers adopted the technology. The company's gross profit rose 57% year-over-year to $548,000 with a margin of 30%, up slightly despite foreign exchange impacts. However, IceCure posted a net loss of $8.8 million for H1 2026 compared to $7 million in the prior year period due to higher operating and finance expenses. U.S. revenue increased by 64% to $608,000 following FDA clearance for early-stage breast cancer treatment, with over 30 active installed sites representing a 70% growth since June 2025.
Topics: funding gross_profit net_loss revenue